Member Info for JohnLaw

£40K delayed buy from yesterday morning seems to have been responsible - it took so long it must have had to shake out all the weak hands.
16-Nov-20 08:06:30 1.24 3,224,718 Sell* 1.25 1.30 39.99k (Bid/Ask at the time 1.10/1.20)

Does the 30 Nov msci cap changenot have to be RNS'd or have i missed that RNS?

No - i cannot see that is any any way price sensitive.

I think it would be remarkable if the timetable did not slip. The FDA are going to be rather busy in the next weeks with clearing Covid related business. Lupus will, unfortunately, have to wait.

Yes, but EUA would need dispensation from LSE for non-disclosure "Exception (to the Guidance on the dissemination of price sensitive information )
9.8 If a company considers that disclosure to the public of information required by paragraph 9.1 or 9.2 to be notified to a Regulatory Information Service might prejudice the company's legitimate interests, the UK Listing Authority may grant a dispensation from the relevant requirement."

I do not think that disclosure of a resource upgrade would qualify for exemption as that would be likely to be in the company's interests, rather than prejudicial.

Can someone please point me to information about how well this technology is protected by patents worldwide?

Leeds’ indie heroes Kaiser Chiefs have announced their huge return to London for a very special live streamed gig from O2 Academy Brixton on 28 November, exclusively on MelodyVR.
https://ventsmagazine.com/2020/11/12/kaiser-chiefs-announce-live-from-london-at-o2-academy-brixton-on-melodyvr/

Are we there yet?

I do not think relisting and a broker's note are connected

I do not think relisting and a broker's note are connected

The Lupuzor platform has the potential to treat other auto immune conditions such as CIDP, Rheumatoid Arthritis, Crohn’s Disease, Covid-19 cytokine storms and Asthma = $$$billions. Plans are to begin proof of concept testing for CIDP within a few months. Time to market if successful is short in view of the extent of knowledge about Lupuzor. How many AIM-listed drug development companies have late-stage clinical assets of this calibre?

There is antifungal BioAMP-B. Its target competitor (>$400m sales) carries a high risk of liver damage. There follows swiftly BioGlucagon for hypoglycaemia. Target market $500m.
Both of these can reach the market by 2022 according to Chairman Tim McCarthy– that is very near term in this business.

Any one of the above products are potential company-makers. There is also an expanding and advancing portfolio of other products in development. And there is the investment in Incanthera which is rising in value nicely.

Lots of tricks to this pony.

Corrrection - i meant the actual outcome of product success is 1 or 0. Meantime there are guesses as to the probability of a 1 or 0

Miavoce is perfectly correct. The long term value of SCLP (today) is the sum the values of (product 1 x probability of suceess + product 2 x probability of success .......Product X x probability of success). The probabilities are either 1 or 0. If any ONE of those probabilties prove to be 1 we are hugely undervalued. If all probabilities are 0 then SCLP is worth 0. The short term price while each probability is uncertain is just the product of market noise, guesswork and uninformed shyte.

Sorry double negative there. Correction:

My bet is none of them is posting on IMM chat. GLA.

Average stock market returns over time in UK are 5.5%*. Some years more some years less. The US average is 9.1%. If you can significantly beat that you are either really lucky (this week/month/year) or, if you can repeat it every year, you are the one-in-a million (?) investor gifted with what is called flair - a quality science cannot define. If you are that investor with flair you are already famous outside of this chat room. But say one in a thousand has flair. If so for us to know three investors with flair would be a one in billion shot. My bet is none of them are not posting on IMM chat. GLA.
* https://fourpillarfreedom.com/visualizing-stock-market-returns-in-23-different-countries/

Monday: Vaccine works: OMG no need for tests - Sell!
Friday: Vaccine works - OMG need for even more tests - Buy!
So damn my Friday thinking last week - if only I had realised how stupid this market is I would have ignored rationality and waited for Monday. Bugger

Great news for so many reasons. It also features in the Telegraph, CNN etc.

Sorry you object to factual information being posted. I am invested in Vela - look back and you will see why I think this is a valuable investment. It just so happens don't like to see lies being propagated by unprincipled rampers.

No need to guess:
"The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomised double-blind study. Eligible patients will be randomly assigned to one of two groups (AZD1656 plus usual care or placebo plus usual care) on a 1:1 basis
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
Actual Study Start Date : August 12, 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021"

https://clinicaltrials.gov/ct2/show/NCT04516759

Yes - you are wrong. Completion expected March 2021.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
https://clinicaltrials.gov/ct2/show/NCT04516759

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomised double-blind study. Eligible patients will be randomly assigned to one of two groups (AZD1656 plus usual care or placebo plus usual care) on a 1:1 basis
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
Actual Study Start Date : August 12, 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Next investment? Bought with what?

An index does not need to hold any shares at all - it is just arithmetic based on closing prices.. However a fund that purports to match (or beat) the index will hold all (or some) of the shares in the index.